Arecor Therapeutics annual ebitda
2022
2023
2024
2025
Arecor Therapeutics's calculated EBITDA was £1.2M for fiscal 2025.
View full Arecor Therapeutics company overview| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £1.2M | £5.9M | — |
| 2024 | 2024-12-31 | −£4.7M | £3.7M | — |
| 2023 | 2023-12-31 | −£8.4M | £1.7M | — |
| 2022 | 2022-12-31 | −£10.1M | — | — |
Between the periods ended 2022-12-31 and 2025-12-31, Arecor Therapeutics's ebitda increased from −£10.1M to £1.2M, a change of £11.3M.
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arecor Therapeutics source filings ↗